Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2011-04-12
2011-04-12
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S316000, C544S319000, C544S320000, C514S269000, C514S275000
Reexamination Certificate
active
07923556
ABSTRACT:
Compounds having the formula (I),and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein:two of X1, X2, and X3are N, and the remaining one of X1, X2, and X3is —CR1;R1is hydrogen or —CN; andN, G, Z, R2, R3, R4, R5, and R6are described in the specification.Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
REFERENCES:
patent: 4200750 (1980-04-01), Warner, Jr. et al.
patent: 4873248 (1989-10-01), Katoh et al.
patent: 5022915 (1991-06-01), Prisbylla
patent: 5250530 (1993-10-01), Giencke et al.
patent: 5250533 (1993-10-01), Heinemann et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 5945418 (1999-08-01), Bemis et al.
patent: 5977103 (1999-11-01), Adams et al.
patent: 6087496 (2000-07-01), Anantanarayan et al.
patent: 6130235 (2000-10-01), Mavunkel et al.
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6251914 (2001-06-01), Adams et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6531479 (2003-03-01), Wang et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 6720427 (2004-04-01), Sanner et al.
patent: 2002/0010170 (2002-01-01), Salituro et al.
patent: 2004/0039033 (2004-02-01), Atwal et al.
patent: 2007/0027155 (2007-02-01), Bakthavatchalam et al.
patent: 2008/0132509 (2008-06-01), Blum et al.
patent: 2201083 (1974-04-01), None
patent: 2001089452 (2001-04-01), None
patent: 2003206230 (2003-07-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 02/22607 (2002-03-01), None
patent: WO 03/029248 (2003-04-01), None
patent: WO 03/099820 (2003-12-01), None
patent: WO 2004/011443 (2004-02-01), None
patent: WO 2004/043467 (2004-05-01), None
patent: WO 2004043467 (2004-05-01), None
patent: WO 2004/071440 (2004-08-01), None
patent: WO 2004/080979 (2004-09-01), None
patent: WO 2004/087679 (2004-10-01), None
patent: WO 2004084824 (2004-10-01), None
patent: WO 2004/096797 (2004-11-01), None
patent: WO 2005/079801 (2005-09-01), None
patent: WO 2005/113514 (2005-12-01), None
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Cohen et al., Current Opinion in Chemical Biology, 3,459-465, 1999.
Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer et al., Bio/Technology, 1994, 12:320.
Powell et al., British Journal of Dermatology, 141″ 802-810, 1999.
Golub et al., Science, 286, 531-537, 1999.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Ahn, H., et al., “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”, Journal of Medicinal Chemistry, vol. 40(14), pp. 2196-2210, (1997).
Bundgaard, H, et al., “A Textbook of Drug Design and Development”, Chapter 5, Design and Application of Prodrugs, pp. 113-191, (1991).
Bundgaard, H., “Design of Prodrugs”, Table of Contents, (1985).
Bundgaard, H., “Means to Enhance Penetration”, Advanced Drug Delivery Reviews, vol. 8, pp. 1-38, (1992).
Collman, J.P., et al., “The Formation of Peptide Bonds in the Coordination Sphere of Cobalt(III)”, Journal of the American Chemical Society, vol. 89(24), pp. 6096-6103, (1967).
Davila, M, et al., “LIM Kinase 1 Is Essential for the Invasive Growth of Prostate Epithelial Cells”, The Journal of Biological Chemistry, vol. 278(38), 36868-36875, (2003).
Greene, T. W, et al,, Protective Groups in Organic Synthesis, Second Edition, Wiley, NY, Table of Contents, (1991).
Henry, J. R., et al., “p38 mitogen-activated protein kinase as a target for drug discover”, Drugs of the Future, vol. 24(12), pp. 1345-1354, (1999).
Moreland, L.W., et al., “Etanercept Therapy in Rheumatoid Arthritis”, Annals of Internal Medicine, vol. 130(6), pp. 478-486, (1999).
Raingeaud, J. et a., “MKK3- and MKK6-Regulated Gene Expression is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Cellular Biology, vol. 16(3), pp. 1247-1255, (1996).
Rankin, E.C.C, et al. “The Therapeutic Effects of an engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (DCP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, pp. 334-342, (1995).
Salituro, F. G., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, pp. 807-823, (1999).
Suyama, E., et al., “LIM kinase-2 targeting as a possible anti-metastasis therapy”, The Journal of Gene Medicine, vol. 6, pp. 357-363, (2004).
Widder, KS., “Methods in Enzymology”, Drug and Enzyme Targeting, vol. 112, pp. 309-396, (1985).
Yoshioka, K., et al., “A role for LIM kinase in cancer invasion”, Proceedings of the National Academy of Sciences. vol. 100(12), pp. 7247-7252, (2003).
He Liqi
Leftheris Katerina
Lin Shuqun
Lin Tai-An
Seitz Steven P.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Duncan Lauralee L.
LandOfFree
Phenyl-substituted pyrimidine compounds useful as kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenyl-substituted pyrimidine compounds useful as kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenyl-substituted pyrimidine compounds useful as kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741023